Not following ACR practice guidelines potentially leads to unnecessary workups and extra health care costs.
There is significant variability among radiologists’ choice of imaging modality for evaluation of benign and pathologic nipple discharge, according to a study published in the American Journal of Roentgenology.
Researchers from Arizona and Georgia undertook an online survey to assess radiologists' choice of imaging modality for the evaluation of clinical symptoms of physiologic nipple discharge (e.g., bilateral discharge, multiple-duct orifices, and yellow, green, or white color) and pathologic nipple discharge (e.g., unilateral discharge, single-duct orifices, spontaneous and serous discharge, and clear or bloodstained color).
A total of 8,170 surveys were sent to lead interpreting physicians at mammography facilities accredited by the American College of Radiology (ACR). The researchers received 849 responses, for a response rate of 10.4%. For the workup of physiologic nipple discharge, recommendations included:
Practitioners in nonacademic settings and those who read breast images during less than 50% of their practice were significantly more likely to recommend DM (with or without US), compared with SM (the standard recommended by the ACR). Practitioners who read breast images less than 50% of the time were also more likely to recommend MRI after conventional imaging revealed negative results.
Related article: Mammography Focuses on Patient Comfort to Improve Test Rates
For the workup of pathologic nipple discharge, recommendations included:
Nonacademic providers and those who read breast images less than 50% of the time were significantly less likely to recommend DM plus US (the standard recommended by the ACR), compared with DM only.
The researchers concluded that there is variability in imaging modality selection among U.S. radiologists handling the imaging workflow for benign and pathologic nipple discharge. Radiologists do not uniformly follow ACR practice guidelines, which potentially leads to unnecessary workups and extra healthcare costs.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.